why choose us

First received: September 13, 2023

Clinical Trial: A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myelodysplastic Syndromes

Study Type: INTERVENTIONAL


Official Title: A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.

Read more